ISSN 3080-7638(Print)
ISSN 3080-7646(Online)
版权信息

ISSN 3080-7638(Print)
ISSN 3080-7646(Online)
CODEN:SQHAA7
(国际标准连续出版物标识符·
全球唯一标识符)
分配机构:美国化学文摘社(CAS)

编委会
主编
郑永波
同行评议专家

副主编
徐爱芳/南通市第二人民医院
马燕/广西贺州市人民医院
黄美莹/贵州工商职业学院
李佳怡/姜晨/张海洋
蒋惠如/杨毅宁/冯智博
汪亚坤/王菡侨/李波
(以上排名不分先后顺序)
编委
 
编委会助理
周鹏
期刊主页
在线投稿
申请编委/副主编/同行评议专家
索引/检索/存档
DOI
ICI World of Journals
哥白尼索引期刊数据库(波兰)

EuroPub
欧洲学术出版中心数据库(英国)

巴西联邦政府
LivRe(科学在线图书馆)

Open Access Library(OALib)
开放存取资源图书馆

RCCSE中国学术期刊收录(武大)
ESJI欧亚科学期刊索引(哈萨克斯坦)
KIND CONGRESS KC
Research Bible
Sci Online
Baidu Baike 
Editing and Publishing
Quest Press Limited
Address
7th Floor,D, No.19,Palawak
Lane, Macau
Telephone
+853 6881 9699
Email
QuestPress@hotmail.com
Web site
http://qkhl.scionline2025.com/
 

  首页 -> 往期阅览-> 2025年
《实用全科护理学》( ISSN3080-7638、EISSN3080-7646 ) 发布者:Quest Press 发布日期:2025/10/9
10.12479/questpress-syqkhlx.20250123 Open Access 下载2 浏览30

 

静脉输液港在肿瘤患者长期化疗中的应用与维护管理

崔洪玲
射阳县人民医院,江苏盐城,224300
摘要:目的 探寻静脉输液港在肿瘤患者长期化疗时的应用成效及维护管理对策,为增强化疗依从性、降低并发症发生率提供支撑。方法 本研究为前瞻性对照研究,选取我院2024 年1 月1 日至2024 年12 月31 日期间接受长期化疗的100 例肿瘤患者,按照入院顺序采用随机数字表法分为观察组与对照组,每组50 例。观察组采用静脉输液港进行化疗,对照组采用外周静脉穿刺方式。两组均由专人实施护理干预,对比分析两组患者在静脉通路使用时间、并发症发生率、患者满意度及治疗依从性等方面的差异。结果 观察组静脉通路平均使用时间为(215.6±17.4)天,显著长于对照组的(13.2±4.1)天,(P<0.001);观察组并发症发生率为8.00%,低于对照组的28.00%,(P<0.05);观察组患者满意度达92.00%,对照组为70.00%(P<0.01);观察组治疗依从性优于对照组(P<0.05)。结论 在肿瘤患者的长期化疗中,静脉输液港展现出通路维持久、并发症少以及患者依从性与满意度高的特点,伴以科学的维护管理手段,能显著提高化疗质量以及患者的生活质量,应当在临床推广运用。
关健词:静脉输液港;肿瘤;化疗;并发症;维护管理
 
Application and maintenance management of intravenous infusion port in long-term chemotherapy for cancer patients
Hongling Cui
Sheyang County People's Hospital, Yancheng Jiangsu 224300,China
Abstract:Objective To explore the efficacy and maintenance management strategies of venous infusion ports in long-term chemotherapy for cancer patients, so as to improve chemotherapy compliance and reduce complication rates.Methods This prospective controlled study enrolled 100 cancer patients undergoing long-term chemotherapy in our hospital from January 1, 2024, to December 31, 2024. They were randomly divided into an observation group and a control group (n=50 each) using a random number table based on admission order. The observation group received chemotherapy via a venous infusion port, while the control group underwent peripheral venous puncture. Both groups received dedicated nursing interventions. Comparisons were made between the two groups regarding venous access duration, complication rates, patient satisfaction, and treatment compliance.Results The average venous access duration in the observation group was (215.6±17.4) days, significantly longer than that of the control group (13.2±4.1)days,(P<0.001). The complication rate in the observation group was 8.00%, lower than the control group's 28.00%,(P<0.05). Patient satisfaction in the observation group reached 92.00%, compared to 70.00% in the control group (P<0.01).Treatment compliance was also better in the observation group (P< 0.05).Conclusion In long-term chemotherapy for cancer patients,venous infusion ports demonstrate advantages such as prolonged access duration, fewer complications, and higher patient compliance and satisfaction. With proper maintenance and management, they can significantly improve chemotherapy quality and patients' quality of life, making them worthy of clinical promotion.
Keywords:Venous infusion port; Cancer; Chemotherapy; Complications; Maintenance management
 
 
 
  Peer Review
同行评审
Editorial Services
编辑服务
Research Ethics Policy
研究伦理政策
Contributorship & Authorship
贡献者与署名
About Quest Press / Macau Sino Int. Med. Press
关于 Quest Press 与 Macau Sino Int. Med. Press
  Global Indexing
全球索引
Copyright Licensing
版权许可
Data Sharing Policy
数据共享政策
Appeal/Correction/Retraction
申诉/更正/撤回
  Online Submission
线上投稿
To the Librarian
致图书馆员
Open Access Statement
开放获取声明
Misconduct Handling Policy
处理不端行为政策
  Content Licensing
内容许可
Guidelines for Reviewers
审稿人指南
Quality Control Mechanism
质量把控机制
Academic Misconduct Screening Policy
学术不端筛查政策
  Advertising Policy
广告政策
Article Processing Charge (APC)
文章处理费
Publication Ethics Policy
出版伦理政策
Call for Editorial Board Members/Associate Editors/Peer Reviewers/Editors-in-Chief
诚邀编委、副主编、同行评审专家及主编